Questions:

1. Some Non RMS sarcomas have a specific tendency to develop regional tumor spread. Which ones and what is your advice regarding the initial work-up for these tumors?
2. For NTRK infantile fibrosarcoma, as new targeted drugs that inhibits NTRK fusion transcript, like larotrectinib (Vitrakvi) seems really efficient, what is the role of this new drug in the overall therapeutic strategy, nowadays?
3. For malignant peripheral Nerve Sheath tumors (MPNST), is there any new promising therapies in the near future?
4. Could you summarize in few words, the overall therapeutic strategy for a desmoid type fibromatosis in children?
5. What are your suggested second line therapy in case of a relapse of a synovial sarcoma despite previous surgery, radiotherapy and chemotherapy?